Aligos Therapeutics Presents Positive Data at APASL 2025
Positive Clinical Data Presentation: Aligos Therapeutics presented promising results from their Phase 1 and Phase 2a studies at the APASL 2025 meeting, showcasing significant antiviral activity of ALG-000184 for chronic hepatitis B and notable reductions in liver fat with ALG-055009 for metabolic dysfunction-associated steatohepatitis (MASH).
Therapeutic Potential: The data suggests that ALG-000184 may become a first-line therapy for chronic hepatitis B, while ALG-055009 shows potential as a best-in-class treatment for MASH, with both therapies demonstrating good tolerability and no viral resistance observed.
Trade with 70% Backtested Accuracy
Analyst Views on ALGS
About ALGS
About the author
Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth
- Leadership Change: Onco3R Therapeutics announced the appointment of Dr. Lawrence M. Blatt as Chair of the Board, bringing extensive drug development and strategic leadership experience to guide the company's next growth phase.
- Industry Expertise: Blatt has served as CEO of Aligos Therapeutics since 2018 and previously led global infectious diseases and vaccines at Janssen Pharmaceuticals, providing a strong industry background.
- Product Development Potential: Onco3R's O3R-5671, designed for autoimmune diseases based on over 12 years of preclinical and clinical data, shows promising safety and efficacy, with potential applications in various autoimmune conditions.
- Clinical Trial Plans: The Phase 1 trial for O3R-5671 is set to commence in 2026, assessing safety and pharmacokinetics while utilizing biomarker tests to gain insights into its immune modulation mechanisms.
Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan
- Stock Option Grant: Aligos Therapeutics granted a total of 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting top talent and enhancing employee loyalty, in compliance with Nasdaq listing rules.
- Incentive Plan Implementation: The stock options were granted under Aligos' 2024 Inducement Plan, ensuring that new hires benefit from equity incentives during their tenure, thereby improving overall team stability and execution.
- Exercise Price Setting: The exercise price of the stock options is set at the closing price on the grant date, ensuring that new employees can share in the value growth of the company, further motivating them to contribute to its development.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, a structure that not only helps retain talent but also aligns employee goals with the company's objectives.
Aligos Grants 14,100 Stock Options to New Employees as Inducement
- Incentive Program Launch: Aligos Therapeutics granted 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting high-quality talent and strengthening the team to drive the company's R&D progress in liver and viral diseases.
- Equity Incentive Structure: The stock options have an exercise price equal to the closing price on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, ensuring long-term employee retention and enhancing company stability.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company adheres to relevant regulations while attracting new employees, thereby reducing compliance risks and enhancing corporate image.
- Strategic Talent Acquisition: By implementing this incentive measure, Aligos not only attracts new talent but also accelerates its innovation process in liver and viral disease treatments through enhanced team expertise, further improving its market competitiveness.
Aligos Therapeutics Presents Positive HBV and Weight Loss Data at HEP-DART 2025
- HBV Treatment Potential: Aligos showcased positive data from a 96-week study of 300mg pevifoscorvir sodium monotherapy at HEP-DART 2025, indicating its potential as a first-line therapy for chronic hepatitis B, thereby reinforcing the company's leadership in the liver disease sector.
- Significant Weight Loss Effects: New data reveals that the combination of ALG-055009 with semaglutide can achieve up to 40% weight loss, significantly enhancing efficacy compared to monotherapy, highlighting its potential value in treating obesity and metabolic diseases.
- Clinical Research Advancements: In diet-induced obese mice, the combination of ALG-055009 with incretin receptor agonists demonstrated synergistic effects, further validating its importance in future combination therapies and potentially increasing the company's market share in the cardiometabolic space.
- Commitment to Continuous Innovation: Aligos has made promising advancements in early-stage HBV and HDV research, showcasing its ongoing commitment to developing next-generation therapies in liver and viral diseases, which enhances investor confidence in its future growth potential.
Aligos Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Stock Options Granted: Aligos Therapeutics announced the grant of non-qualified stock options for 27,400 shares to newly hired employees as part of their 2024 Inducement Plan, effective October 15, 2025.
Vesting Schedule: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, contingent on continued employment.
Biotech Stocks Surge After Hours Due to Trial Advancements, Funding Developments, and Anticipated Milestones
Prime Medicine Inc. Updates: Shares rose 8.14% after positive Q2 earnings, a narrowed net loss, and early clinical data from its CGD program. The company also completed a $144.2 million public offering and has upcoming IND filings for Wilson's Disease and AATD planned for 2026.
Elutia Inc. Developments: The stock increased by 10.17% following the announcement of clinical data showing significant improvements in reoperations for cardiac devices. Elutia will showcase its EluPro BioEnvelope at an upcoming technology exchange event.
Aligos Therapeutics Inc. Progress: Shares rose 2.79% after presenting preclinical studies at the International HBV Meeting, supporting its Phase 2 B-SUPREME trial. Upcoming catalysts include continued trial enrollment and a scheduled earnings report in November 2025.
Bionano Genomics Inc. Offering: The stock fell 35.74% due to a $10 million public offering announcement but rebounded 6.74% in after-hours trading. The funds will be used for working capital, and recent publications highlighted the utility of its Optical Genome Mapping technology.
Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth
- Leadership Change: Onco3R Therapeutics announced the appointment of Dr. Lawrence M. Blatt as Chair of the Board, bringing extensive drug development and strategic leadership experience to guide the company's next growth phase.
- Industry Expertise: Blatt has served as CEO of Aligos Therapeutics since 2018 and previously led global infectious diseases and vaccines at Janssen Pharmaceuticals, providing a strong industry background.
- Product Development Potential: Onco3R's O3R-5671, designed for autoimmune diseases based on over 12 years of preclinical and clinical data, shows promising safety and efficacy, with potential applications in various autoimmune conditions.
- Clinical Trial Plans: The Phase 1 trial for O3R-5671 is set to commence in 2026, assessing safety and pharmacokinetics while utilizing biomarker tests to gain insights into its immune modulation mechanisms.
Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan
- Stock Option Grant: Aligos Therapeutics granted a total of 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting top talent and enhancing employee loyalty, in compliance with Nasdaq listing rules.
- Incentive Plan Implementation: The stock options were granted under Aligos' 2024 Inducement Plan, ensuring that new hires benefit from equity incentives during their tenure, thereby improving overall team stability and execution.
- Exercise Price Setting: The exercise price of the stock options is set at the closing price on the grant date, ensuring that new employees can share in the value growth of the company, further motivating them to contribute to its development.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, a structure that not only helps retain talent but also aligns employee goals with the company's objectives.
Aligos Grants 14,100 Stock Options to New Employees as Inducement
- Incentive Program Launch: Aligos Therapeutics granted 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting high-quality talent and strengthening the team to drive the company's R&D progress in liver and viral diseases.
- Equity Incentive Structure: The stock options have an exercise price equal to the closing price on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, ensuring long-term employee retention and enhancing company stability.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company adheres to relevant regulations while attracting new employees, thereby reducing compliance risks and enhancing corporate image.
- Strategic Talent Acquisition: By implementing this incentive measure, Aligos not only attracts new talent but also accelerates its innovation process in liver and viral disease treatments through enhanced team expertise, further improving its market competitiveness.
Aligos Therapeutics Presents Positive HBV and Weight Loss Data at HEP-DART 2025
- HBV Treatment Potential: Aligos showcased positive data from a 96-week study of 300mg pevifoscorvir sodium monotherapy at HEP-DART 2025, indicating its potential as a first-line therapy for chronic hepatitis B, thereby reinforcing the company's leadership in the liver disease sector.
- Significant Weight Loss Effects: New data reveals that the combination of ALG-055009 with semaglutide can achieve up to 40% weight loss, significantly enhancing efficacy compared to monotherapy, highlighting its potential value in treating obesity and metabolic diseases.
- Clinical Research Advancements: In diet-induced obese mice, the combination of ALG-055009 with incretin receptor agonists demonstrated synergistic effects, further validating its importance in future combination therapies and potentially increasing the company's market share in the cardiometabolic space.
- Commitment to Continuous Innovation: Aligos has made promising advancements in early-stage HBV and HDV research, showcasing its ongoing commitment to developing next-generation therapies in liver and viral diseases, which enhances investor confidence in its future growth potential.
Aligos Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Stock Options Granted: Aligos Therapeutics announced the grant of non-qualified stock options for 27,400 shares to newly hired employees as part of their 2024 Inducement Plan, effective October 15, 2025.
Vesting Schedule: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, contingent on continued employment.
Biotech Stocks Surge After Hours Due to Trial Advancements, Funding Developments, and Anticipated Milestones
Prime Medicine Inc. Updates: Shares rose 8.14% after positive Q2 earnings, a narrowed net loss, and early clinical data from its CGD program. The company also completed a $144.2 million public offering and has upcoming IND filings for Wilson's Disease and AATD planned for 2026.
Elutia Inc. Developments: The stock increased by 10.17% following the announcement of clinical data showing significant improvements in reoperations for cardiac devices. Elutia will showcase its EluPro BioEnvelope at an upcoming technology exchange event.
Aligos Therapeutics Inc. Progress: Shares rose 2.79% after presenting preclinical studies at the International HBV Meeting, supporting its Phase 2 B-SUPREME trial. Upcoming catalysts include continued trial enrollment and a scheduled earnings report in November 2025.
Bionano Genomics Inc. Offering: The stock fell 35.74% due to a $10 million public offering announcement but rebounded 6.74% in after-hours trading. The funds will be used for working capital, and recent publications highlighted the utility of its Optical Genome Mapping technology.
